UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

Clinical pharmacology and therapeutics, 2018-11, Vol.104 (5), p.836-864

2018

Volltextzugriff (PDF)

Predicting Oral Absorption for Compounds Outside the Rule of Five Property Space

Journal of pharmaceutical sciences, 2021-06, Vol.110 (6), p.2562-2569

2021

Volltextzugriff (PDF)

Investigating AI's Role in Enhancing Multi-Sensory Experiences in Public Spaces

ARCHive-SR (Online), 2024-08, Vol.8 (2), p.12-30

2024

Volltextzugriff (PDF)

A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters

Drug metabolism and disposition, 2019-07, Vol.47 (7), p.768-778

2019

Volltextzugriff (PDF)

Genetic Diversity in Drug Transporters: Impact in African Populations

Clinical and translational science, 2020-09, Vol.13 (5), p.848-860

2020

Volltextzugriff (PDF)

Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition

Xenobiotica, 2018-03, Vol.48 (3), p.300-313

2018

Volltextzugriff (PDF)

Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects

Xenobiotica, 2020-02, Vol.50 (2), p.160-179

2020

Volltextzugriff (PDF)

Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects

European journal of clinical pharmacology, 2012-05, Vol.68 (5), p.697-708

2012

Volltextzugriff (PDF)

Cytochrome P450 1B1 (CYP1B1) pharmacogenetics : Association of polymorphisms with functional differences in estrogen hydroxylation activity

Cancer research (Chicago, Ill.), 2000-07, Vol.60 (13), p.3440-3444

2000

Volltextzugriff (PDF)

Physiologically based pharmacokinetic modeling for assessing the clinical drug–drug interaction of alisporivir

European journal of pharmaceutical sciences, 2014-10, Vol.63, p.103-112

2014

Volltextzugriff (PDF)

Role of the Alanine at Position 363 of Cytochrome P450 2B2 in Influencing the NADPH- and Hydroperoxide-Supported Activities

Archives of biochemistry and biophysics, 1998-02, Vol.350 (2), p.324-332

1998

Volltextzugriff (PDF)

Role of Glutamic Acid 216 in Cytochrome P450 2D6 Substrate Binding and Catalysis

Biochemistry (Easton), 2003-02, Vol.42 (5), p.1245-1253

2003

Volltextzugriff (PDF)

Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps

The Journal of biological chemistry, 2002-09, Vol.277 (37), p.33711-33719

2002

Volltextzugriff (PDF)

Diversity in the Oxidation of Substrates by Cytochrome P450 2D6: Lack of an Obligatory Role of Aspartate 301−Substrate Electrostatic Bonding

Biochemistry (Easton), 2002-09, Vol.41 (36), p.11025-11034

2002

Volltextzugriff (PDF)

Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective

Clinical pharmacology and therapeutics, 2022-09, Vol.112 (3), p.573-592

2022

Volltextzugriff (PDF)

Expression of Human Cytochrome P450 2B6 in Escherichia coli: Characterization of Catalytic Activity and Expression Levels in Human Liver

Archives of biochemistry and biophysics, 2000-04, Vol.376 (1), p.206-216

2000

Volltextzugriff (PDF)

Oxidation of Phenethylamine Derivatives by Cytochrome P450 2D6: The Issue of Substrate Protonation in Binding and Catalysis

Biochemistry (Easton), 2001-11, Vol.40 (47), p.14215-14223

2001

Volltextzugriff (PDF)

Intestinal Transporter-Associated Drug Absorption and Toxicity

Drug Transporters in Drug Disposition, Effects and Toxicity, 2019, Vol.1141, p.361-405

2019

Volltextzugriff (PDF)

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria

Drug metabolism and disposition, 2013-07, Vol.41 (7), p.1347-1366

2013

Volltextzugriff (PDF)

Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model

Journal of pharmaceutical sciences, 2017-05, Vol.106 (5), p.1439-1451

2017

Volltextzugriff (PDF)

Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3

Pulmonary pharmacology & therapeutics, 2022-02, Vol.72, p.102097-102097, Article 102097

2022

Volltextzugriff (PDF)

Survey of pharmaceutical industry's best practices around in vitro transporter assessment and Implications for Drug Development: Considerations from the IQ Transporter Working Group

Drug metabolism and disposition, 2024-05, p.DMD-AR-2023-001587

2024

Volltextzugriff (PDF)

Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline

Xenobiotica, 2017-08, Vol.47 (8), p.682-696

2017

Volltextzugriff (PDF)

A plasma concentration of α-ketoglutarate influences the kinetic interaction of ligands with organic anion transporter 1

Molecular pharmacology, 2014-07, Vol.86 (1), p.86-95

2014

Volltextzugriff (PDF)

1 – 25 von 125

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(111)
Mit Volltextzugriff
(97)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug‐Drug Interaction Evaluation: Perspectives From the International Transporter Consortium

Predicting Oral Absorption for Compounds Outside the Rule of Five Property Space

Investigating AI's Role in Enhancing Multi-Sensory Experiences in Public Spaces

A Systematic In Vitro Investigation of the Inhibitor Preincubation Effect on Multiple Classes of Clinically Relevant Transporters

Genetic Diversity in Drug Transporters: Impact in African Populations

Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition

Disposition of asciminib, a potent BCR-ABL1 tyrosine kinase inhibitor, in healthy male subjects

Intestinal OATP1A2 inhibition as a potential mechanism for the effect of grapefruit juice on aliskiren pharmacokinetics in healthy subjects

Cytochrome P450 1B1 (CYP1B1) pharmacogenetics : Association of polymorphisms with functional differences in estrogen hydroxylation activity

Physiologically based pharmacokinetic modeling for assessing the clinical drug–drug interaction of alisporivir

Role of the Alanine at Position 363 of Cytochrome P450 2B2 in Influencing the NADPH- and Hydroperoxide-Supported Activities

Role of Glutamic Acid 216 in Cytochrome P450 2D6 Substrate Binding and Catalysis

Oxidation of methoxyphenethylamines by cytochrome P450 2D6. Analysis of rate-limiting steps

Diversity in the Oxidation of Substrates by Cytochrome P450 2D6: Lack of an Obligatory Role of Aspartate 301−Substrate Electrostatic Bonding

Clinical Relevance of Hepatic and Renal P‐gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective

Expression of Human Cytochrome P450 2B6 in Escherichia coli: Characterization of Catalytic Activity and Expression Levels in Human Liver

Oxidation of Phenethylamine Derivatives by Cytochrome P450 2D6: The Issue of Substrate Protonation in Binding and Catalysis

Intestinal Transporter-Associated Drug Absorption and Toxicity

Variability in P-glycoprotein inhibitory potency (IC₅₀) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria

Survey of Pharmaceutical Industry's Best Practices around In Vitro Transporter Assessment and Implications for Drug Development: Considerations from the International Consortium for Innovation and Quality for Pharmaceutical Development Transporter Working Group

Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model

Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3

Survey of pharmaceutical industry's best practices around in vitro transporter assessment and Implications for Drug Development: Considerations from the IQ Transporter Working Group

Clinical disposition, metabolism and in vitro drug-drug interaction properties of omadacycline

A plasma concentration of α-ketoglutarate influences the kinetic interaction of ligands with organic anion transporter 1

Suchergebnisse filtern